The Food and Drug Administration authorized for marketing the first at-home over-the-counter test for COVID-19 using a traditional premarket review pathway rather than emergency use authorities. The Cue COVID-19 Molecular Test detects SARS-CoV-2 in nasal swabs from adults with symptoms of upper respiratory infection. Subsequent devices of the same type with the same intended use that demonstrate substantial equivalence may now use the agency’s 510(k) pathway to obtain clearance, FDA said. 
  
“The FDA continues to proactively work with test developers that desire to market their products beyond emergency use authorities,” said Jeff Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “This is part of the FDA’s broader effort to advance the development and availability of at-home tests for a variety of medical conditions to expand patient access to testing.” 

Related News Articles

Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…